**HEADLINE: CUBAN DUMPS SHARKS for GUNS: Billionaire Quietly Funds Anti-Monopoly Assault on Big Pharma**

HEADLINE: CUBAN DUMPS SHARKS FOR GUNS: Billionaire Quietly Funds Anti-Monopoly Assault on Big Pharma

DALLAS, TX — Mark Cuban has silently executed a $50M pivot from TV fame to outright market warfare. The “Shark Tank” star and billionaire owner of the Dallas Mavericks is no longer just a talking head. In a move that has competitors scrambling, Cuban has deployed his cost-plus drug company, Mark Cuban Cost Plus Drug Company, to directly acquire three generic drug manufacturers. The result is an unprecedented vertical integration that slashes insulin and EpiPen prices below cost.

Cuban told The Wall Street Journal, “I’m not writing checks to charities for visibility. I’m building a machine that breaks the monopoly in real time.” His play: sell essential drugs at 10% above manufacturing cost—with zero middlemen. Industry insiders are calling it the most aggressive, profit-smashing disruption in biotech since the 1980s. The stock of three major pharmacy middlemen dropped an average of 4% on the news.

The bottom line: Cuban is betting his liquidity can strangle an opaque $500B supply chain. Investors should watch for a hostile takeover of a PBMs (Pharmacy Benefit Managers) stock price collapse by Q4. This is no longer a hobby—it’s a hostile takeover of the pricing mechanism itself.